Nasdaq suspends Windtree (WINT): -80% in 24 hours, moving to OTC and BNB strategy in jeopardy

Related

Citi bvnk investment signals Wall Street shift to stablecoin rails

Citi bvnk investment marks a notable step in the...

Bitcoin cycle dead: Hayes argues halving no longer dictates markets

Bitcoin cycle dead — Arthur Hayes argues the classic...

Luxembourg: we were the first country in the Eurozone to invest in Bitcoin

Luxembourg wealth fund has allocated 1% of its portfolio...

Gemini Australia expansion gains AUSTRAC registration and Sydney hires

Gemini Australia expansion is underway: the US exchange has...

Share

The suspension from Nasdaq for Windtree Therapeutics (ticker WINT), due to non-compliance with listing requirements and accompanied by an intraday collapse of –80%, has sparked strong fears among investors and raised questions about the recent initiative of treasury in BNB (initial commitment of $60 million with potential up to $200 million), indicating an already fragile financial balance.

According to the collected data, the stock went from about $0.48 before the notice to $0.11 at the close on August 21, 2025, confirming the very substantial intraday loss. Industry analysts monitoring small-cap biotech companies note that similar situations typically lead to a compression of capitalization and a significant reduction in liquidity in the first weeks following the delisting.